

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



06 May 2025

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Change in Key Managerial Personnel - Chief Financial Officer

This is to inform that Mr. C S Muralidharan, EVP - Finance & Accounts and Chief Financial Officer, will be superannuating from Sun Pharma. After a thorough process, Ms. Jayashree Satagopan has been identified as Mr. Muralidharan's successor. The Board of Directors of the Company has, at its meeting held today, i.e., 06 May 2025 (which concluded at 06:20 P.M. IST), considered the following;

1. Noted superannuation of Mr. C. S. Muralidharan, Chief Financial Officer, effective from 01 July 2025. The board placed on record appreciation for Mr. Muralidharan's contribution and leadership at Sun Pharma.

Mr. Muralidharan has played a significant role in Sun Pharma's growth trajectory and strengthening governance mechanisms. Specifically, he made vital contributions in aligning business objectives with finance, Sun Pharma's acquisitions and subsequent integration, improving transparency and reporting timelines and achieving higher productivity in finance through transformation. He also played an important role in our sustainability journey in the areas of laying out objectives, reporting, and coordination.

2. Approved appointment of Ms. Jayashree Satagopan as the Chief Financial Officer and Key Managerial Personnel effective from 01 July 2025. Ms. Satagopan would join Sun Pharma on 09 May 2025 as EVP - Finance & Accounts and Chief Financial Officer (Designate), and shall assume the position of Chief Financial Officer effective from 01 July 2025.

The board has approved the appointment of Ms. Satagopan based on the recommendations of the Nomination and Remuneration Committee and the Audit Committee.

[Annexure A](#), enclosed herewith, provides the particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Part A of Schedule III.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.

Reaching People. Touching Lives.

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel. : (91-22) 4324 4324
Fax : (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details	
1	Name	Mr. C. S. Muralidharan	Ms. Jayashree Satagopan
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Superannuation of Mr. C. S. Muralidharan as the Chief Financial Officer, effective from 01 July 2025	Mr. C. S. Muralidharan, the Chief Financial Officer, will be superannuating on 01 July 2025. In view of his superannuation, Ms. Jayashree Satagopan is appointed as the Chief Financial Officer effective from 01 July 2025.
3	Date of appointment / re-appointment / cessation (as applicable) & term of appointment / re-appointment;	01 July 2025	01 July 2025.
4	Brief profile (in case of appointment);	Not Applicable	Brief profile provided below
5	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable	Not Applicable

Brief Profile of Ms. Jayashree Satagopan

Jayashree is a Commerce Graduate from the University of Madras, and holds professional qualifications - Chartered Accountant (CA), Cost and Management Accountant (CMA), and Company Secretary (CS).

In her last role, she was associated with Coromandel International Ltd., part of the Murugappa group, as President Corporate and Chief Financial Officer.

In a career spanning over three decades, she was also associated with PI Industries, International Paper Company, GE Healthcare, Ford India, and Ashok Leyland. Jayashree brings with her experience of managing multiple portfolios, cutting across various geographies, in diverse sectors such as agri-solutions, healthcare, manufacturing, and automotive.